Impedance Cardiographic (ICG) Assessment of Pregnant Women With Severe Hypertension to Assess Impact of Standard Therapy (ICASH)
|ClinicalTrials.gov Identifier: NCT01248169|
Recruitment Status : Completed
First Posted : November 25, 2010
Last Update Posted : December 12, 2013
|Condition or disease|
|Pregnancy; Proteinuria, With Hypertension (Severe Pre-eclampsia) Delivery; Proteinuria, With Gestational Hypertension (Pre-eclampsia, Severe) Pregnancy; Hypertension, Gestational Hypertension, With Albuminuria (Severe Pre-eclampsia)|
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||Impedance Cardiographic Assessment of Gravidas With Severe Hypertension (ICASH)to Assess Impact of Standard Therapy on Hemodynamic Parameters - A Pilot Study|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||November 2013|
This group will receive administration of the antihypertensive Hydralazine for the attempted control of their blood pressure and stabilization of their hemodynamic state.
This group will receive administration of the antihypertensive Labetalol for the attempted control of their blood pressure and stabilization of their hemodynamic state.
- Usefulness of Impedance Cardiography (ICG) in pregnant women with hypertension [ Time Frame: 36 ]ICG test is performed on pregnant women before receiving any antihypertensive medication. Labetalol and Hydralazine, two ot the most commonly used antihypertensives to treat high blood pressure in pregnant women will be used in this study.
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01248169
|United States, Mississippi|
|Wiser Hospital for Women and Infants at the University of Mississippi Medical Center|
|Jackson, Mississippi, United States, 39216|
|Principal Investigator:||James N Martin, MD||SOM-Obstetrics & Gynecology|